These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25330500)

  • 1. Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial.
    Sen H; Lam MK; Tandjung K; Basalus MW; de Man FH; Louwerenburg JH; Stoel MG; van Houwelingen GK; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; van der Palen J; von Birgelen C
    EuroIntervention; 2014 Oct; 10(6):664-71. PubMed ID: 25330500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.
    Sen H; Lam MK; Tandjung K; Löwik MM; Stoel MG; de Man FH; Louwerenburg JH; van Houwelingen GK; Linssen GC; Doggen CJ; Basalus MW; von Birgelen C
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):74-81. PubMed ID: 24585502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial.
    van Houwelingen KG; Sen H; Lam MK; Tandjung K; Löwik MM; de Man FH; Louwerenburg JH; Stoel MG; Hartmann M; Linssen GC; Doggen CJ; von Birgelen C
    Catheter Cardiovasc Interv; 2015 Feb; 85(3):E76-82. PubMed ID: 25339110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial.
    Löwik MM; Lam MK; Sen H; Tandjung K; van Houwelingen KG; de Man FH; Stoel MG; Louwerenburg JH; Linssen GC; Doggen CJ; von Birgelen C
    EuroIntervention; 2015 Mar; 10(11):1276-9. PubMed ID: 25136888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial.
    Tandjung K; Basalus MW; Sen H; Stoel MG; van Houwelingen KG; Louwerenburg JH; de Man FH; Linssen GC; Saïd SA; Kleijne MA; van der Palen J; von Birgelen C
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):396-405. PubMed ID: 23359390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
    J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial.
    van Houwelingen KG; Lam MK; Löwik MM; Danse PW; Tjon Joe Gin RM; Jessurun GA; Anthonio RL; Sen H; Linssen GCM; IJzerman MJ; Doggen CJM; von Birgelen C
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1152-1159. PubMed ID: 27595181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
    J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial.
    Lam MK; Sen H; van Houwelingen KG; Löwik MM; van der Heijden LC; Kok MM; de Man FH; Linssen GC; Tandjung K; Doggen CJ; von Birgelen C
    Am Heart J; 2015 Jan; 169(1):69-77. PubMed ID: 25497250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
    von Birgelen C; Sen H; Lam MK; Danse PW; Jessurun GA; Hautvast RW; van Houwelingen GK; Schramm AR; Gin RM; Louwerenburg JW; de Man FH; Stoel MG; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; Basalus MW; Doggen CJ; Tandjung K
    Lancet; 2014 Feb; 383(9915):413-23. PubMed ID: 24183564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
    J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stents.
    Tandjung K; Basalus MW; Muurman E; Louwerenburg HW; van Houwelingen KG; Stoel MG; de Man FH; Jansen H; Huisman J; Linssen GC; Droste HT; Nienhuis MB; von Birgelen C
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):524-30. PubMed ID: 22109857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and non-enrolled TWENTE registry.
    Sen H; Lam MK; Tandjung K; Löwik MM; van Houwelingen KG; Stoel MG; Louwerenburg HW; de Man FH; Linssen GC; Grandjean JG; Doggen CJ; von Birgelen C
    Int J Cardiol; 2014 Oct; 176(3):885-90. PubMed ID: 25168098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.